drugset
drugset / Trial / NCT05139082

Study of CDK4/6 Inhibitor Combined With PD-L1 Monoclonal Antibody in the Treatment of PD-1/PD-L1 Resistance and Abnormal Cell Cycle Digestive System Tumors

NCT05139082 ↗

Phase 1/2 Unknown 60 enrolled Peking University
NaSingle-groupOpen-labelTreatment

Summary

This study intends to explore the effectiveness and safety of CDK4/6 inhibitor (TQB3616) combined with PD-L1 monoclonal antibody (TQB2450) in the treatment of PD-1/PD-L1 monoclonal antibody resistance and abnormal cell cycle digestive system tumors, through prospective Explore to provide more evidence-based medical evidence for precision immunotherapy for patients with digestive system tumors.

Timeline

Start
2021-11-24
Primary completion
2023-10-01
Completion
2023-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Benmelstobart Monoclonal antibody 1200 mg Intravenous
Subject TQB3616 Small molecule 120 mg Oral
Subject TQB3616 Small molecule 150 mg Oral
Subject TQB3616 Small molecule 180 mg Oral

Indications

digestive system neoplasm